Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Leo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 23, 2022
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Leo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Hematology
Study Phase : Phase IV
Sponsor : Leo Pharma | Sunnybrook Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 12, 2021
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Sponsor : Leo Pharma | Sunnybrook Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Leo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Therapeutic Anticoagulation Strategy for Acute Chest Syndrome
Details : Undisclosed
Product Name : Innohep
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 20, 2015
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Leo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Leo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 09, 2014
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Leo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Nephrology
Study Phase : Phase IV
Sponsor : McMaster University | Leo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Use of Tinzaparin for Anticoagulation in Hemodialysis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 28, 2013
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Nephrology
Highest Development Status : Phase IV
Sponsor : McMaster University | Leo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 18, 2013
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Use Of Fragmin In Hemodialysis
Details : Undisclosed
Product Name : Fragmin
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 18, 2013
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Hematology
Study Phase : Phase IV
Sponsor : Netherlands Organisation for Scientific Research | Aspen API | CHU of Saint Etienne: French Ministry of Health Grant | Rotunda Hospital: Definitive Interventions and Feasibility Awards (DIFA) 2017 (sponsor of the Irish part of the study))
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 11, 2013
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Sponsor : Netherlands Organisation for Scientific Research | Aspen API | CHU of Saint Etienne: French Ministry of Health Grant | Rotunda Hospital: Definitive Interventions and Feasibility Awards (DIFA) 2017 (sponsor of the Irish part of the study))
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase IV
Sponsor : Aarhus University Hospital | Leo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 08, 2011
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Sponsor : Aarhus University Hospital | Leo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Innohep
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 25, 2010
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable